Trava's appeal is that the price is the price. All-inclusive plans at $147 a month, standard titration ladders, no separate fees appearing at dose three. After comparing providers whose real cost only emerges later, that clarity is welcome.
The model is medication delivery, and the Charter measures something else entirely. Nothing here is organised around your history, which produces zeroes across the first three rows.
Here is how Trava Health reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
Medication and service are bundled into one monthly figure with no separate consultation or adjustment charges, which is why the cost row scores partial rather than lower — the pricing is genuinely legible. The pharmacy is not disclosed publicly, so whether increments can be customised is an open question, and one worth asking given the ladder-based approach.
A fixed ladder assumes people progress at a similar pace and land in a similar place. That assumption fits many and not everyone, and it has no built-in mechanism for someone who needs longer at a step or a different increment. How much flexibility exists in practice depends on the clinicians rather than the model, which makes it worth asking about before you start.
Put these to Trava Health in writing, and keep the reply.
Trava rates low on this Charter because it addresses none of the whole-person rows, and a standard ladder is the opposite of individualised dosing. As affordable, clearly-priced medication access it is sound. As the place where you finally get seen properly, it is not designed for that.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.